Know Cancer

or
forgot password

Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast


Phase 3
40 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast


Inclusion Criteria:



- Stage 0, I or II breast cancer.

- Invasive ductal, papillary, mucinous, tubular, medullary or lobular carcinoma.

- Ductal carcinoma in situ (DCIS) alone.

- No lymph invasion (L0) and no hemangiosis (V0).

- Lesions of > 3 cm diameter, histopathologically confirmed.

- pN0/pNmi (a minimum of 6 nodes in specimen, or a negative sentinel node is
acceptable); in the case of DCIS alone axillary staging (e.g. sentinel lymph node
biopsy) is optional.

- M0.

- Clear resection margins at least 2 mm in any direction; by lobular histology or DCIS
histology only the resection margins must be clear at least 5 mm.

- For DCIS only: lesions must be classified as low or intermediate risk group (Van Nuys
Prognostic Index <8).

- Unifocal and unicentric DCIS or breast cancer.

- Age >= 40 years.

- Time interval from final definitive breast surgical procedure to the start of
external beam therapy or to brachytherapy is less than 12 weeks (84 days). If
patients receive chemotherapy the radiotherapy can be started before systemic
treatment (within 12 weeks). The radiation therapy can be also given in the interval
between the chemotherapy courses. It is also possible to start radiation therapy
after chemotherapy is completed according local protocols as soon as possible within
4 weeks after chemotherapy.

- Signed study-specific consent form prior to randomization.

Exclusion Criteria:

- Stage III or IV breast cancer.

- Surgical margins that cannot be microscopically assessed.

- Extensive intraductal component (EIC).

- Paget's disease or pathological skin involvement.

- Synchronous or previous breast cancer.

- Prior malignancy (< 5 years prior to enrollment in study) except non-melanoma skin
cancer or cervical carcinoma FIGO 0 and I if patient is continuously disease-free.

- Pregnant or lactating women.

- Collagen vascular disease.

- The presence of congenital diseases with increased radiation sensitivity, for example
Ataxia telangiectatica or similar.

- Psychiatric disorders.

- Patient with breast deemed technically unsatisfactory for brachytherapy.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Local control

Outcome Time Frame:

5-years, 10 ten-years

Safety Issue:

No

Principal Investigator

Vratislav Strnad, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University Hospital Erlangen, Germany

Authority:

Germany: Ethics Commission

Study ID:

GEC-ESTRO APBI Trial

NCT ID:

NCT00402519

Start Date:

November 2004

Completion Date:

November 2014

Related Keywords:

  • Breast Cancer
  • accelerated partial breast irradiation
  • multicatheter brachytherapy
  • high dose rate brachytherapy
  • pulsed dose rate brachytherapy
  • Breast Neoplasms
  • Carcinoma, Intraductal, Noninfiltrating

Name

Location